Ophthalmology

Eye
#AMD #Endogena Therapeutics #FDA #Geographic atrophy #Ophthalmology

FDA gives green light for AMD treatment trials

The US Food and Drug Administration (FDA) has granted clearance for Endogena's Investigational New Drug (IND) application for EA 2351, a potential treatment for geographic atrophy (GA). GA is an advanced form of age-related macular degeneration (AMD). The first-in-human study is set to commence in 2024. The company is currently… Read More

#News #Regulatory

Structure of the eye
#AMD #Boehringer Ingelheim #CDR-Life #Collaboration #Geographic atrophy #Ophthalmology #Phase I trial

Antibody treatment for geographic atrophy enters clinical trials

Collaborators Boehringer Ingelheim and CDR-Life have commenced a Phase I evaluation of BI 771716, their antibody fragment-based treatment developed to preserve the vision of people with geographic atrophy (GA). Boehringer Ingelheim and CDR-Life entered a licensing agreement in May 2020 and announced the… Read More

#Editor's Choice #News

Eye
#AMD #Drug targets #Louisiana State University #Neuroscience #Ophthalmology

Discovery provides new therapeutic approaches to AMD

New research suggests that age-related macular degeneration (AMD) decreases an essential fatty acid, preventing the formation of a class of protective molecules and reducing repair potential – a discovery that may open new therapeutic avenues for AMD. The study shows that AMD decreases peripheral retinal docosahexaenoic… Read More

#News

Test for AMD
#AMD #Astellas Pharma #FDA #Geographic atrophy #Ophthalmology

FDA approves Izervay for geographic atrophy

The US Food and Drug Administration (FDA) has approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The new complement C5 inhibitor is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at… Read More

#News #Regulatory

Eye
#Antibody Fragments #Boehringer Ingelheim #CDR-Life #Geographic atrophy #Ophthalmology

Antibody fragment-based drug could slow geographic atrophy

CDR-Life has reached a development milestone with its antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy (GA). Boehringer Ingelheim and CDR-Life entered a collaboration and licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate… Read More

#News

RNA
#Laboratoires Théa #Mergers and acquisitions #Ophthalmology #ProQR Therapeutics #RNA

Théa acquires ProQR’s RNA ophthalmic assets

ProQR Therapeutics and Laboratoires Théa have announced an agreement in which ProQR will divest its late-stage ophthalmic assets, sepofarsen and ultevursen, to Théa. Under the terms of the agreement, ProQR will receive an initial payment of €12.5M and will also be eligible for up to €135M in further development, regulatory,… Read More

#Business & Investment #News

Patient receiving eye drops
#CS Pharmaceuticals #Dry eye #Mergers and acquisitions #Ophthalmology

CS acquires AxeroVision’s dry eye disease pipeline

CS Pharmaceuticals (CSP) has acquired AxeroVision, a company developing novel therapies for the treatment of dry eye disease (DED) and other ophthalmic inflammatory diseases that address the underlying inflammatory processes. Darren Mercer, Chief Executive of CSP, said: “We are thrilled to acquire AxeroVision, and in particular the pipeline product AXR-270… Read More

#Business & Investment #News

Human eye
#Cell and gene therapy #Gene therapy #Krystal Biotech #Ophthalmology

First-of-its-kind gene therapy restores vision in DEB patient

A dystrophic epidermolysis bullosa (DEB) patient at the Bascom Palmer Eye Institute, University of Miami, US, has regained his vision after being the first person to receive a formulation of gene therapy Vyjuvek suitable for the eyes. DEB is a rare genetic condition that makes the… Read More

#News #Trending News

Eye
#AMD #Aviceda Therapeutics #Geographic atrophy #Nanomedicine / nanotechnology #Ophthalmology #Phase II trial

Novel glycan-coated nanoparticle enters trials for geographic atrophy

Aviceda Therapeutics has dosed the first patient in its Phase II SIGLEC trial investigating AVD-104 as a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is a novel glycan-coated nanoparticle, supported by a strong pre-clinical in vivo efficacy and safety profile. Read More

#News

Diabetic eye disease
#Diabetes #Eye health #John Hopkins Medicine #Ophthalmology #Preclinical development

Experimental drug could prevent diabetic eye disease

New study results show that an experimental drug may prevent or slow vision loss in people with diabetes. The researchers at Wilmer Eye Institute, Johns Hopkins Medicine used mouse as well as human retinal organoids and eye cell lines in their investigations. Eye conditions… Read More

#Editor's Choice #News

Structure of the eye
#Genetics / genomics #Ophthalmology #Regenerative Medicine #Université de Montréal

New technique could restore vision in retinal disease

Researchers at Université de Montréal have discovered a way to potentially restore vision in patients suffering from degenerative retinal disease. Published in Proceedings of the National Academy of Sciences, the research was led by UdeM medical professor Michel Cayouette, Director of Cellular Neurobiology Research at the… Read More

#Editor's Choice #News

Ophthalmologist looks at retinal scan
#Artificial intelligence (AI) #Endogena Therapeutics #Ophthalmology #Phase I trial #Phase II trial #Retinitis pigmentosa

Retinitis pigmentosa drug proved safe in Phase I/IIa study

Endogena Therapeutics has completed the dose-escalation stage of its Phase I/IIa study of EA-2353 in retinitis pigmentosa (RP) with no clinically relevant or dose-limiting adverse events. Given the positive safety and tolerability profile, the study will now enrol patients into the expansion cohort, using the highest… Read More

#News

Woman having an eye test
#Cell and gene therapy #Clinical trials #Gene therapy #Genetics / genomics #GenSight Biologics #Ophthalmology

Five-year data show gene therapy safe for ND4-LHON

GenSight Biologics has revealed pooled safety data from five clinical studies of lenadogene nolparvovec (Lumevoq), the largest cohort of ND4-LHON (Leber hereditary optic neuropathy) patients studied after gene therapy treatment. The data confirms the good overall safety profile of the product in terms of systemic and… Read More

#News

Testing visual acuity
#Aura Biosciences #Cancer research #Melanoma #Oncology #Ophthalmology #Phase II trial

Choroidal melanoma drug preserved vision in Phase II study

Aura Biosciences has announced positive interim Phase II safety and efficacy data for belzupacap sarotalocan (bel-sar) as a first-line treatment for patients with early-stage choroidal melanoma with suprachoroidal administration.  The results showed a statistically significant reduction in tumour growth rate compared to each patient’s documented growth rate… Read More

#Cancer Research #News

Screening patient for AMD
#Clinical research #Complement Therapeutics #Dry AMD #Gene therapy #Geographic atrophy #Ophthalmology

Non-interventional geographic atrophy study launches

Complement Therapeutics (CTx) has enrolled the first patient in its study of people diagnosed with geographic atrophy (GA).  The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA, by enabling the identification of patients with complement-driven AMD for future… Read More

#News

#Endogena Therapeutics #FDA #Ophthalmology #Orphan drugs #Priority Review #Retinitis pigmentosa

FDA Fast Track Designation for retinitis pigmentosa treatment

The US Food and Drug Administration (FDA) has designated the investigation of Endogena Therapeutics’ EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track development programme.   Fast Track is a process designed to enable patients to benefit earlier from important new drugs for serious conditions. … Read More

#News